Page 10 - Stephen Schultz News Today

London, UK - 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental

London, UK 3 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder . The study expands COMPASS’s research pipeline in psilocybin therapy with COMP360, ...

Investegate announcements from COMPASS Pathways, Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK 20 October 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients. Within one week of a single ...

Investegate announcements from COMPASS Pathways, COMPASS Pathways is granted new US patent for crystalline psilocybin

London, UK 19 October 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office . This is COMPASS’s first patent with claims covering its Form A hydrate psilocybin. The Form A hydrate is distinct from the anhydrate psilocybin for which ...

/PRNewswire/ -- Advisor Group, the nations largest network of independent wealth management firms, today announced the successful recruitment to its network...

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 Partnership being developed with

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

(0) LONDON, June 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. The data) from the randomised, double-bli...